Medexus Pharmaceuticals (TSE:MDP) Price Target Raised to C$6.25

Medexus Pharmaceuticals (TSE:MDP) had its price objective hoisted by equities research analysts at Ventum Financial from C$5.00 to C$6.25 in a research report issued to clients and investors on Thursday,BayStreet.CA reports. The firm currently has a “buy” rating on the stock. Ventum Financial’s price target suggests a potential upside of 57.43% from the stock’s current price.

MDP has been the topic of a number of other research reports. Stifel Nicolaus upped their price objective on shares of Medexus Pharmaceuticals from C$4.50 to C$6.00 in a report on Thursday. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial upgraded shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, January 22nd. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. Finally, Ventum Cap Mkts upgraded shares of Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 17th. Two research analysts have rated the stock with a buy rating and five have assigned a strong buy rating to the company. According to MarketBeat, Medexus Pharmaceuticals currently has an average rating of “Strong Buy” and a consensus target price of C$6.13.

Medexus Pharmaceuticals Trading Down 0.7 %

Shares of TSE:MDP traded down C$0.03 during mid-day trading on Thursday, reaching C$3.97. The company had a trading volume of 122,000 shares, compared to its average volume of 192,164. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56. The firm has a market cap of C$97.38 million, a price-to-earnings ratio of 79.40 and a beta of 1.96. The company’s 50-day moving average price is C$3.37 and its 200-day moving average price is C$2.76.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.